- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04085380
Digestive Colonisation by Highly Resistant Bacteria (CODBAHRE) (CODBAHRE)
Identification of New Highly Antibiotic-resistant Bacteria Carriage Risk Factors to Optimize the Detection and Medical Care for Carriers Patients
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
CODBAHRE is a french, regional study, involving 9 centers. Recruitment will take place in all the departments of the centers involved under the supervision of the Infection Control Team.
All patients hospitalized more than 24 hours, on a given day are eligible for the protocol, except the patients unable to answer the questionnaire.
After collecting the non-opposition of the patient, patients will be screened by rectal swab and a questionnaire will be completed.
Each sample will be analyzed to detect eXDR carrying patients.
The carrying patients will be followed during 6 months to estimate the proportion of the population which developped a bacterial infection. This information will be collected by a retrospective telephone survey of carrying patients.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Paris, Frankrig
- HEGP
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Hospitalization of more than 24 hours
- Give his no objection
Exclusion Criteria:
- Hospitalization in psychiatry
- Unwilling to participate
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Risk factors
Tidsramme: at inclusion
|
Identification of risk factors for digestive colonisation by highly resistant bacteria Lifestyle questionnaire: environment, diet, medical history and result of the rectal swab
|
at inclusion
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Prevalence of multidrug-resistant bacteria will be determined by the number of patients who have been detected at least one multidrug-resistant bacteria referred to the number of patients sampled
Tidsramme: 1 day
|
Number of patient carrying a Multidrug-resistant bacteria in Ile de France
|
1 day
|
|
Prevalence of co-carrying patients of eXDR and ESBL will be determined by the number of patients who carrying eXDR and ESBL referred to the number of patients sampled
Tidsramme: 1 day
|
Estimate the prevalence of "co-carrying patients of eXDR and ESBL in the Ile de France
|
1 day
|
|
Prevalence will be determined by the number of patients who carrying at least one Multidrug-resistant bacteria referred to the number of patients sampled
Tidsramme: 1 day
|
Establish whether there are significant differences between hospital associated with the recruitment of these institutions.
|
1 day
|
|
Proportion of patients carrying "eXDR" who will develop an infection with the same germ referred to the number of eXDR carriers
Tidsramme: 6 months
|
Estimate the proportion of patients colonized by a "eXDR" who will develop an infection with the same germ.
|
6 months
|
|
Cross-transmission rate of eXDR
Tidsramme: 1 day
|
Number of cross transmissions during the study by comparing the eXDR bacteria genotypes in the same unit
|
1 day
|
|
Description of the association between strains (RAPD, infrared Biotyper, genome sequencing).
Tidsramme: 16 months
|
Identify possible links between strains
|
16 months
|
|
Description of resistance and virulence characteristics between strains (RAPD, infrared Biotyper, genome sequencing).
Tidsramme: 16 months
|
Characterize the resistance and virulence factors of certain strains.
|
16 months
|
|
Comparison of the frequency of positive presence of eXDR bacteria obtained between culture technic and molecular biology technic
Tidsramme: 16 months
|
Comparison culture vs molecular biology technics.
|
16 months
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Najiby Kassis-Chikhani, PhD, AP-HP, Hôpital Européen Georges Pompidou, Paris
- Ledende efterforsker: Jean-Ralph Zahar, PhD, AP-HP, Hôpitaux Avicenne, Jean Verdier, et René Muret, Bobigny
- Ledende efterforsker: Véronique Moulin, AP-HP, Hôpital Corentin Celton, et Vaugirard
- Ledende efterforsker: Pierre Frange, PhD, AP-HP, Hôpital Necker enfants malades, Paris
- Ledende efterforsker: Christine Lawrence, PhD, AP-HP, Hôpital Raymond Poincaré, Garches
- Ledende efterforsker: Frédéric Barbut, PhD, AP-HP-Hôpital Saint Antoine, Paris
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- CODBAHRE
- APHP180561 (Anden identifikator: AP-HP)
- 2019-A01226-51 (Anden identifikator: IDRCB)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-delingstidsramme
IPD-delingsadgangskriterier
Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team.
Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Risikofaktor
-
Pakistan Institute of Living and LearningAfsluttetPsykose | At Risk Mental State (ARMS)Pakistan
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)AfsluttetFørste episode psykose (FEP) | At Risk Mental State (ARMS)Forenede Stater
-
Cairo UniversityShaimaa Mostafa; Yasmin Zakaria; Ibrahim Fawzy; Mona Aboulghar; Mona FouadAfsluttet
-
Tanta UniversityAfsluttet
-
The First Affiliated Hospital of Soochow UniversityRekrutteringCore Binding Factor Akut Myeloid Leukæmi | KIT-mutationsrelaterede tumorerKina
-
Taipei Medical University WanFang HospitalAfsluttetParonychia | Epidermal Growth Factor Receptor InhibitorTaiwan
-
Chang Gung Memorial HospitalAfsluttetParonychia | Epidermal Growth Factor Receptor InhibitorTaiwan
-
D.O. Ott Research Institute of Obstetrics, Gynecology...Aktiv, ikke rekrutterendeInfertilitet | Chlamydia Trachomatis-infektion | Antichlamydia antistoffer | Tubal Factor InfertilitetDen Russiske Føderation
-
University Hospital, Strasbourg, FranceRekrutteringHæmoragiske lidelser | Ekstrinsisk Pathway Factor Deficiency | Hepatocellulær insufficiens med koagulopatiFrankrig
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Guangzhou First People's Hospital; Sun... og andre samarbejdspartnereRekrutteringCore Binding Factor Akut Myeloid LeukæmiKina